Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 3Stomach Neoplasms 2Sarcoma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Smoking Cessation 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Pain, Postoperative 1Neurofibrosarcoma 1Neoplasm Metastasis 1Mucopolysaccharidosis I 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Glioblastoma 1Fibrosarcoma 1Colorectal Neoplasms 1Cachexia 1Breast Neoplasms 1

Interventions

Temozolomide 203Radiotherapy 118Bevacizumab 93Radiation 40Magnetic Resonance Spectroscopy 28Irinotecan 27Carmustine 25Surgical Procedures, Operative 24Lomustine 21Erlotinib Hydrochloride 19Chemotherapy, Adjuvant 18Carboplatin 17temsirolimus 13Drug Therapy 13O(6)-benzylguanine 12Nivolumab 12sargramostim 11Sirolimus 11Radiotherapy, Intensity-Modulated 11Radiotherapy, Conformal 11Sorafenib 10Radiosurgery 10Imatinib Mesylate 10Everolimus 10pembrolizumab 9motexafin gadolinium 9Vorinostat 9Thalidomide 8IL13-PE38 8Gefitinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Glioblastoma × Combined Modality Therapy × Clear all
NCT00805961 2021-12-08

RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM

SCRI Development Innovations, LLC

Phase 2 Completed
68 enrolled 8 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡